Financial Times on DNA-guided prescribing

The Financial Times highlights the Netherlands as a pioneer in pharmacogenetic prescribing - enabled by the clinical infrastructure powered by iGene Pharmaco

The Netherlands leads in DNA-guided prescribing

The Financial Times recently featured the Netherlands as a global pioneer in implementing pharmacogenetic testing within everyday healthcare. In the article, Professor Ron van Schaik (Erasmus MC) describes how patients can use a DNA medication passport to ensure that prescriptions are tailored to their genetic profile.
When a patient presents this passport at the pharmacy, pharmacists can immediately adjust medication doses based on validated pharmacogenetic data - making therapy both safer and more effective.

This national model is supported by Dutch pharmacogenetic guidelines (DPWG), evolving reimbursement structures for clinically relevant testing and a secure digital infrastructure connecting laboratories, prescribers and pharmacists. Powered by iGene Pharmaco.

A turning point in personalised pharmacotherapy

Across the world, health systems increasingly recognise that genetic variation profoundly affects how patients respond to medicines. The Financial Times positions the Dutch system within this global shift: Reducing adverse drug reactions, preventing hospital admissions, and improving outcomes by integrating pharmacogenetic insights into routine care. This approach marks a key transition, from reactive prescribing to preventive pharmacotherapy guided by DNA.

iGene Pharmaco powers the pharmacogenetic infrastructure behind this innovation

At iGene Pharmaco, we are proud to provide the pharmacogenetic testing, data interpretation and clinical decision support infrastructure that underpins this nationwide implementation.
Our technology enables leading institutions, such as Erasmus MC, to deliver validated, guideline-based pharmacogenetic reports directly within existing clinical and pharmacy systems without disrupting the workflow. All within a safe, compliant, and healthcare-ready environment.

Through this collaboration, iGene Pharmaco contributes to a healthcare ecosystem where every prescription can be informed by a patient’s DNA profile.

Read the full article in the Financial Times

Trusted by leading pharmacy organisations and labs

Private. Compliant. Built for clinical environments.

With iGene Pharmaco, pharmacists, doctors, and lab technicians can collaborate securely within one platform to deliver better, more personalised patient care.

Private by design

Testing with iGene is 100% anonymous. DNA is strictly separated from personal information.

Based on the latest guidelines

We update our reports whenever CPIC/DPWG guidelines change.

Certified and compliant

ISO 27001 certified and compliant with clinical guidelines. Designed for use in healthcare settings.

Explore more cases

Pharmacogenetic Passport for Gamedi

iGene Pharmaco provides secure pharmacogenetic testing and reporting for Gamedi’s Pharmacogenetic Passport, supporting personalised and preventive care.

Pharmacogenetic Passport for Gamedi

iGene Pharmaco provides secure pharmacogenetic testing and reporting for Gamedi’s Pharmacogenetic Passport, supporting personalised and preventive care.
Applying pharmacogenetics in primary care

Pharmacist Vince Maar applies pharmacogenetic DNA testing to optimise medication reviews with GPs, improving therapy safety and outcomes in primary care.

Applying pharmacogenetics in primary care

Pharmacist Vince Maar applies pharmacogenetic DNA testing to optimise medication reviews with GPs, improving therapy safety and outcomes in primary care.
Erasmus MC DNA app

Academic Hospital Erasmus MC uses iGene Pharmaco’s secure, ISO-certified platform to deliver validated pharmacogenetic dosing advice directly to patients.

Erasmus MC DNA app

Academic Hospital Erasmus MC uses iGene Pharmaco’s secure, ISO-certified platform to deliver validated pharmacogenetic dosing advice directly to patients.

1 3